Health Care & Hospital Law,
Civil Litigation
May 13, 2021
Opioid makers hyped products while downplaying risks, expert testifies
Testifying via Zoom Wednesday, medical marketing expert Matthew Perrie, formerly of the University of Georgia, said the drugmakers named in California’s false advertising suit highlighted the benefits and downplayed the risks associated with prescription opioid-use in their marketing plans.
Drugmakers aggressively marketed opioids while downplaying addiction risks, a medical marketing expert testified in a $50 billion opioid trial in Orange County this week. Meanwhile, a bankruptcy judge in New York contemplated a Chapter 11 reorganization plan that could shield opioid giant Purdue Pharma from future civil suits claiming it fueled the opioid crisis.
Testifying via Zoom Wednesday, medical marketing expert Matthew Perri...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
Enewsletter Sign-up
Related Content
Health Care & Hospital Law, Civil Litigation
Quarter of patients addicted after opioid pain prescription, doctor testifies
By Blaise Scemama
Health Care & Hospital Law, Civil Litigation
State’s expert admits bias against opioids
By Blaise Scemama
Health Care & Hospital Law, Civil Litigation
State witness says drugmakers paid for positive opioid studies
By Blaise Scemama
Constitutional Law, Civil Litigation
Opioid trials remind us of importance of Brady rights
By Nina Marino
Health Care & Hospital Law, Civil Litigation
Expert says California in midst of opioid crisis
By Blaise Scemama
Civil Litigation
State expert’s data questioned by defense in Orange County opioid trial
By Blaise Scemama
Civil Litigation
Defense stymies expert testimony and materials in opioid trial
By Blaise Scemama
Health Care & Hospital Law, Civil Litigation
Objections predominate in opioid trial of 4 pharmaceutical companies
By Blaise Scemama
Civil Litigation
Pharmaceutical CEO’s deposition played in opioid trial
By Blaise Scemama
